secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2023-06-13T23:59:59+00:00
Accession:  0001104659-23-070826
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar delays WM pivotal trial top-line data to H2 2023; pediatric glioma trial to start Q3
--------------------------------------------------------------------------------

- Top-line data from WM CLOVER-WaM trial delayed to H2 2023; 2024 product launch still targeted.
- All 49 sites now active; enrollment accelerated after initial delays from site contracting and regulatory responses.
- Plans to initiate Phase 1b study in pediatric high-grade gliomas in Q3 2023, supported by $2M NCI grant.
- Iopofosine I 131 showed 100% ORR, 83.3% major response rate in Phase 2a WM study (6 patients).
- Fast Track Designation allows 6-month FDA review; platform expands to alpha-emitter, siRNA, and peptide payloads.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923070826/0001104659-23-070826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923070826/tm2318538d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-070826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer